Alnylam Pharmaceuticals (ALNY) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Alnylam Pharmaceuticals Inc (ALNY) 3-Minute Overview > **💡 One-Sentence Summary** > > Simply put, Alnylam is a biotech company commercializing RNA interference medicines, and the stock story right now is about whether its fast-rising drug sales can turn a once pipeline-heavy business into a durable, profitable rare-disease franchise. > **📍 Basic Profile** > > Market Cap **$38.0 billion** · Biotechnology · NASDAQ NMS - GLOBAL MARKET · Price **$284.84** > **⚡ 3 Things You Should Know** > > 1. 💰 **Commercial engine is getting real:** This is no longer just a “science promise” biotech—TTM net margin is positive at **13.46%**, gross margin is a very strong **80.83%**, and recent Q1 revenue growth was reported at **96%**, largely driven by Amvuttra. In other words, the company is showing it can scale real drug sales, not just publish good data. > > 2. 📈 **Growth is strong, but concentration matters:** The business has delivered exceptional multi-year revenue growth (**~53% 3Y CAGR**), and recent momentum looks even better. What’s interesting is that a lot of that excitement is tied to a few key products and indications—especially vutrisiran/Amvuttra—so clinical or competitive setbacks in those franchises would matter a lot. > > 3. ⚠️ **Valuation has cooled, but it’s not exactly cheap:** The stock is down sharply from its 52-week high and trades much closer to its low now, which makes it look less stretched than before. But with a **68x TTM PE** and **9.2x sales**, the market is still pricing in a lot of future success, so this is more of an execution story than a bargain-bin biotech. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Strong💪 | Net margin **13.46%**, unusually solid for a biotech transitioning into commercialization | > | Growth Rate | Fast🚀 | 3-year revenue growth **52.98%**, with recent quarter growth even stronger | > | Financial Health | Moderate💛 | Current ratio **3.13** is strong, but debt-to-equity **3.42** and negative cash flow/share add some pressure | > | Valuation | Pricey | PE **68.15x**, still discounting meaningful pipeline and launch success | --- ## 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** RNAi-based medicines sold primarily to rare-disease patients through specialty commercialization, making money from product sales plus some collaboration-related revenue. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Commercialized RNAi therapies | [Data unavailable] | ↑ | Main value driver; recent growth appears led by Amvuttra | | Collaboration / partner revenue | [Data unavailable] | ↓ | More volatile and lower-quality than recurring product sales | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 80.83% | Top tier | Very high margin suggests strong pricing power typical of successful rare-disease biotech products | | Net Margin | 13.46% | Above Average | Important milestone: the company is actually generating bottom-line profit on a TTM basis | | ROE | 98.29% | Excellent>20% | Looks spectacular on paper, but likely flattered by a thin equity base, so don’t read it as pure operating strength | --- #### 📈 How's the Growth? **Growth Assessment:** High Growth | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | 52.98% (3Y) | [Data unavailable] | Strong, with recent quarter suggesting acceleration | | Profit Growth | [Data unavailable] | [Data unavailable] | Hard to judge cleanly from provided annual data | **Growth Quality:** > This looks like fairly high-quality growth because recent commentary points to **surging product sales**, especially **Amvuttra**, rather than financial engineering. That said, biotech growth can look fantastic when one launch or one label expansion is taking off—basically, it’s healthy growth, but not yet broadly diversified growth. --- #### 💰 Financial Health Check **One Sentence:** Think of it like someone with a strong paycheck and a healthy cash cushion, but also meaningful debt obligations and uneven cash generation. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | Debt/Equity **3.42** | <60% safe | ⚠️High | | Current Ratio | 3.13 | >1.5 healthy | ✅Safe | | Cash Flow | Cash flow/share **-3.62** | >0 | ⚠️Volatile | **Worth noting:** Liquidity looks good in the near term, so this doesn’t look like a funding-stress story right now. The bigger issue is that leverage and cash conversion are not as clean as the income statement might suggest. --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $250.35 - 52-Week High: $495.55 - Current: $284.84, **near the low** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(**14%** position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE **68.15x** | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PE **68.15x** | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > Basically, the market is still betting that Alnylam can keep turning scientific leadership in RNAi into a bigger commercial franchise—especially through Amvuttra/vutrisiran and follow-on label expansion. The lower share price says expectations have cooled, but this stock still needs continued execution; it’s not priced like a mature, slow-growth pharma company. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-04-30 | Q1 2026 results beat estimates; Amvuttra sales reportedly drove 96% Y/Y revenue growth | **Positive** — reinforces the idea that the commercial ramp is real | | 2026-05-04 | New analyses on vutrisiran in ATTR-CM to be presented at Heart Failure 2026 | **Positive** — supportive clinical visibility matters because a lot of the valuation hinges on this franchise | | 2026-05-03 to 2026-05-07 | Multiple analysts maintained positive ratings, though one lowered PT ($450→$445) and another stayed Equal-Weight at $377 | **Mixed Positive** — Street still likes the long-term story, but some enthusiasm has become more measured after stock weakness | --- ## 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 80.83% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | 13.46% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | 98.29% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | 52.98% (3Y CAGR reference) | [Data unavailable] | [Data unavailable] | ↑ | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2026-03-31 | $0.96 | $1.51 | +56.5% Beat 😀 | | 2025-12-31 | $1.15 | $0.82 | -28.5% Miss 😟 | | 2025-09-30 | $0.76 | $2.11 | +177.2% Beat 😀 | | 2025-06-30 | -$0.73 | -$0.51 | +30.6% Beat 😀 | **Earnings Trend Interpretation:** The pattern here is volatile but mostly favorable—3 beats in the last 4 quarters, including two very large positive surprises. In other words, the business is improving, but this is still biotech, so quarter-to-quarter numbers can swing a lot depending on product mix, launch spending, and milestone timing. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 27 firms | 75.0% | | Hold | 9 firms | 25.0% | | Sell | 0 firms | 0.0% | **Target Price:** **$377 ~ $510** (visible range from recent reports; median [Data unavailable]) **vs Current Price:** roughly **32% to 79% upside** versus the recent price, based on cited analyst targets **Insider Activity:** Net **selling** in past 3 months > Recent disclosed insider transactions show repeated sales by Melissa McLaughlin in early April. That’s worth noticing, but not overreading—insider selling can happen for taxes or diversification, while insider buying is usually the stronger positive signal. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Product concentration risk:** A lot of the current excitement appears tied to Amvuttra/vutrisiran → If growth in that franchise slows, the stock’s premium multiple could compress quickly 2. **Clinical/regulatory risk:** This is still a biotech with pipeline and label-expansion dependence → If future trial data disappoints or approvals get delayed, growth expectations may reset 3. **Balance sheet / cash conversion risk:** Liquidity is fine, but debt-to-equity is high and cash flow/share is negative → If commercialization costs stay elevated, accounting profits may not translate cleanly into cash --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Alnylam is one of the best-known RNAi biotech companies, and it’s increasingly becoming a real commercial rare-disease drug business rather than just a pipeline story. > > **Key strength:** Its biggest advantage is strong product momentum paired with biotech-style gross margins, which gives it a credible path to scaling profits if execution continues. > > **Key risk:** The biggest concern is that the stock still depends heavily on continued success from a relatively concentrated set of products and indications, so any stumble can hit both growth and valuation at the same time. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis